

Immune Checkpoint Inhibitors & Immune-Related Adverse Events


The basics!

What are immune checkpoint inhibitors?

- Immune checkpoint inhibitors (ICI) are revolutionizing the management of several potentially devastating malignancies (including melanoma, lung cancer, renal cell carcinoma, sarcoma and others). The reported clinical outcomes with the use of immune check-point inhibitors (ICIs) are very impressive and include complete remission and sustained clinical response in certain types of cancer. The indications for their use continue to expand.

CTLA-4 mediates inhibition in the central lymphoid compartment. CTLA-4 modulates the immune response by:

- Preferentially binding CD80/86 proteins on APCs,
 - Preventing the binding of CD28 (2nd signal needed for T cell activation), and
 - Inhibiting T cell activation.
- Antibodies that block CTLA-4 can lead to ongoing T cell activation. These T cells can then migrate to the peripheral tissues and attack tumor cells.




Abbreviations: APC, antigen-presenting cell; CD28, cluster of differentiation 28; CD80/86, cluster of differentiation 80 or 86; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; MHC, major histocompatibility complex; TCR, T cell receptor.

PD-1 mainly exerts its inhibitory effect on T cells in peripheral tissues. The binding of PD-1 on T cells to PD-L1/PD-L2 on tumor cells can lead to:

- Inhibition of downstream signalling,
- Suppression of T cell function, and
- T cell exhaustion.

Antibodies that block PD-1, PD-L1, and PD-L2 can restore T cell effector function for reactivated anti-tumor response.



Abbreviations: MHC, major histocompatibility complex; PD-1, programmed death 1; PD-L1/2, programmed death-ligand 1 or 2; TCR, T cell receptor.

Ye, C., et al. (2019). "Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments." *Current Treatment Options in Rheumatology* 5(4): 272-289.

- ICI exploit defence processes of host immunity to target malignant processes. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Cell Death 1 inhibitors are T-cell surface receptors that play an important role in immune surveillance. When they are engaged, they have the ability to turn off immune function. Simply speaking, ICIs block these down-regulatory signals, allowing persistent T-Cell activation, thus enhancing immune response and taking advantage of its anti-tumour properties.

What are immune-related adverse events?

- Enhancing the immune response is a double-edged sword as ICI also result in off-target, undesirable inflammatory events that have been termed as "immune related adverse events" (irAEs). In short, persistent immune activation can result in unwelcome immune responses to healthy tissues.
- The reported clinical spectrum of irAEs is broad (Table 1). These events have been described after a single dose of ICI or effects can be delayed and manifest long after treatment is completed.
- These can be transient or can require long term immunosuppression and can occur with any type of ICI.

Skin	Dermatitis, erythroderma, erythema multiform, Stevens-Johnson syndrome, toxic epidermal necrolysis, psoriasis, vitiligo, alopecia
Lungs	Pneumonitis, pleuritis, interstitial lung disease
Gastrointestinal	Colitis, ileitis, pancreatitis, gastritis, perforation
Musculoskeletal	Arthralgias, arthritis, myalgias, myositis, enthesitis, sarcoidosis
Eyes	Conjunctivitis, uveitis, iritis, retinitis, scleritis, episcleritis, blepharitis
Endocrine	Hypo-hyperthyroidism, hypophysitis, hypopituitarism, adrenal insufficiency, type I diabetes
Cardiovascular	Myocarditis, pericarditis, vasculitis
Liver	Hepatitis
Kidneys	Nephritis, lupus-like glomerulonephritis
Neurological	Neuropathy, myelopathy, Guillain-Barre syndrome, Myasthenia gravis-like syndrome, encephalitis, meningitis

Table 1: Spectrum of irAE

How can we predict which patients will develop an irAE?

- Whether specific patient characteristics may aid in predicting those at risk of developing irAEs remains unclear. Several hypotheses have been postulated pertaining to genetic susceptibility, immune biomarkers, properties of gut microbiome and presence of autoantibodies. However, the role of these factors as predictors of complications is ambiguous.

References

- Esfahani, K., et al. (2019). "Adverse events associated with immune checkpoint inhibitor treatment for cancer." *Canadian Medical Association Journal* 191(2): E40
- Ribas, A. and J. D. Wolchok (2018). "Cancer immunotherapy using checkpoint blockade." *Science* 359(6382): 1350.
- Schreiber, R. D., et al. (2011). "Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion." *Science* 331(6024): 1565-1570